港股異動 | 康寧醫院(2120.HK)大漲9%續創新高 月內股價翻逾一倍
格隆匯6月28日丨康寧醫院(2120.HK)延續強勢行情,盤中大漲逾9%,報55港元再創歷史新高價,月內股價翻逾一倍,總市值超40億港元。上週,康寧醫院賣掉房地產業務、決定進一步修訂股權激勵計劃,為再度衝A掃清障礙。隨着公司在精神專科醫療主業上的發展,房地產業務收入在公司收入結構中佔比已不大。業內人士指出,現在我國民營醫院發展勢頭良好,作為公立醫院的一種有效補充,民營醫院蓬勃發展將成為趨勢,行業上的繁榮必將引來資本注入。同時,我國IPO目前正處於新一輪加速期,註冊制的實行也對上市企業的審核速度進一步加快,這也為康寧醫院此次衝擊IPO創造了客觀條件優勢。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.